Newly diagnosed endometrial carcinomas of the MMR-deficient molecular subtype
Investigational medicinal product(s)
DOSTARLIMAB
Eligibility
Age group
18-64 years
Sex
Female
Primary endpoint
Complete response rate
Endpoint detail
Overall response rate, Time to recurrence, Duration of response
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.